A Archives | Report Store | Pharma intelligence

show blocks helper

Sort by Default Order
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products descending

Display 15 Products per page

APL-130277
$10,000.00
APL-130277 (Dainippon Sumitomo/Sunovion) is a sublingual film formulation of apomorphine, a non-ergoline dopamine receptor agonist.
June 21, 2018
More information
Azilect
$10,000.00
Azilect (Teva/Lundbeck/Takeda) contains the pure R-isomer of rasagiline and acts as a selective irreversible monoamine oxidase inhibitor (MAOI), with up to 10 times more potency than selegiline and without metabolizing into amphetamine derivatives.

More information
AMT-061
$10,000.00
AMT-061 is being developed by uniQure as a gene therapy for hemophilia B patients. The product uses an adeno-associated virus as a vector to deliver the highly active Padua factor IX (fIX) variant, which has eightfold to ninefold greater activity than normal, wild-type fIX.
May 4, 2018
More information
Afstyla
$10,000.00
Afstyla is a single-chain recombinant factor VIII (rfVIII) product developed by CSL Behring to have a longer duration of action than standard rfVIII. Endogenously produced fVIII consists of a light chain and a heavy chain fused via a metal ion bridge.

More information
Adynovate
$10,000.00
Adynovate is a long-acting PEGylated recombinant factor VIII (rfVIII) therapy developed by Baxalta and Nektar Therapeutics as a follow-on to Advate (rfVIII; Shire).

More information
Advate
$10,000.00
The recombinant factor VIII (rfVIII) therapy Advate was initially developed by Baxter and then marketed by the pharmaceutical spin-off Baxalta, which is now part of Shire. Advate is the first third-generation rfVIII, and is a follow-on product to Shire’s Recombinate.

More information
Alprolix
$10,000.00
Biogen and Swedish Orphan Biovitrum co-developed Alprolix (recombinant factor IX [rfIX] Fc fusion protein) for the treatment of hemophilia B. The therapy is a recombinant protein consisting of a single fIX fused with the dimeric Fc region of immunoglobulin G-1.

More information
ALKS 3831
$10,000.00
ALKS 3831 is an orally available, fixed-dose combination of samidorphan (ALKS 33) and olanzapine being developed by Alkermes.
April 9, 2018
More information
Abilify/Abilify Maintena
$10,000.00
Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A receptor.

More information
Aristada
$10,000.00
Aristada (aripiprazole lauroxil; Alkermes) is a long-acting injectable formulation of the atypical antipsychotic aripiprazole. It was developed by Alkermes using its proprietary LinkeRx technology, which allows the gradual release of aripiprazole molecules and lowers the drug’s frequency of administration.
March 19, 2018
More information
Advair
$10,000.00
Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol).
February 16, 2018
More information
Atrasentan
$10,000.00
Atrasentan’s Phase III trial is unique including an enrichment period to select responders and those who tolerate the drug for randomization.
February 2, 2018
More information
Apalutamide
$10,000.00
Apalutamide (Johnson & Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently inhibits its nuclear import, as well as its ability to bind to DNA. Apalutamide has a similar mechanism of action to Xtandi (enzalutamide; Pfizer/Astellas).
January 18, 2018
More information
Aranesp
$10,000.00
Aranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment of anemia in chronic kidney disease and chemotherapy-induced anemia.
January 11, 2018
More information
Auryxia
$10,000.00
Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii Pharmaceutical) is a novel oral ferric iron form with hematinic activity, approved for the treatment of anemia in chronic kidney disease.

More information

A

A

APL-130277

Azilect

AMT-061

Afstyla

Adynovate

Advate

Alprolix

ALKS 3831

Abilify/Abilify Maintena

Aristada

Advair

Atrasentan

Apalutamide

Aranesp

Auryxia